| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.00089 | 1 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.001 | 1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.00094 | 1 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.001 | 1 |